Zacks Investment Research Upgrades Allergy Therapeuti (NASDAQ:AGYTF) to “Hold”

Allergy Therapeuti (NASDAQ:AGYTF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, August 30th.

According to Zacks, “Allergy Therapeutics Plc is a specialty pharmaceutical company focused on allergy vaccination. The company’s product pipeline consists of PollinexTrees(R), Pollinex Grasses + Rye(R), Skin Prick Testing, Diagnostic Products and Service. Allergy Therapeutics Plc is based in Worthing, the United Kingdom. “

Shares of Allergy Therapeuti (AGYTF) opened at 0.39 on Wednesday. Allergy Therapeuti has a 52 week low of $0.39 and a 52 week high of $0.39. The firm’s market capitalization is $231.44 million. The firm has a 50 day moving average price of $0.39 and a 200-day moving average price of $0.39.

ILLEGAL ACTIVITY WARNING: This story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://ledgergazette.com/2017/09/17/allergy-therapeuti-agytf-upgraded-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on Allergy Therapeuti (AGYTF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allergy Therapeuti Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeuti and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply